Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Johnson & Johnson (NY:JNJ)

155.79 +0.52 (+0.33%)
Official Closing Price Updated: 7:00 PM EDT, Jul 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
Johnson & Johnson's Subsidiary Discontinues Some Megadyne Electrodes For Pediatric Use
Johnson & Johnson's Megadyne Mega Soft Pediatric Patient Return Electrodes recalled due to patient burns. FDA's Class I recall impacts 21,200 devices. 
Via Benzinga
Johnson & Johnson Is Officially Getting Out of Kenvue (KVUE) Stock
Kenvue stock is up on Monday after Johnson & Johnson announced plans to sell its entire stake in KVUE following last year's spinoff. 
Via InvestorPlace
2 Supercharged Dividend Stocks to Buy and Hold for Years
Consistent passive income is one top goal long-term investors should have for their portfolio. 
Via The Motley Fool
The 7 Most Undervalued Stocks With Strong Fundamentals to Buy in May 2024
Load up on the most undervalued stocks with strong fundamentals for steady growth and passive income over the years. 
Via InvestorPlace
7 Reliable Dividend Stocks to Keep Your Portfolio Upright
Although the idea of reliable dividend stocks isn’t the most exciting concept, these enterprises can help you sleep easy at night. 
Via InvestorPlace
1 Passive Income Vehicle Every Investor Should Own
This healthcare giant is a rock-solid passive income play. 
Via The Motley Fool
Comparing Johnson &amp; Johnson With Industry Competitors In Pharmaceuticals Industry
Via Benzinga
Forget Johnson & Johnson: Buy This Better Healthcare Stock Instead
Johnson & Johnson isn't the ultra-safe stock it used to be. 
Via The Motley Fool
The 3 Best Mutual Funds to Buy in May 2024
Consider the best mutual funds to buy for high returns and low fees. They each have unique strategies meant to maximize returns on capital. 
Via InvestorPlace
The 3 Most Undervalued Stocks to Buy in May 2024
If you're thinking of sitting out the summer, here are three undervalued stocks to buy in May that will protect you from downside tech risk. 
Via InvestorPlace
3 Biotech Stocks to Sell in May Before They Crash & Burn
Discover essential insights on biotech stocks to sell in May to navigate market volatility and safeguard your investment portfolio. 
Via InvestorPlace
Prediction: 3 Sensational Stocks That'll Be Worth Far More Than Tesla 2 Years From Now
Three time-tested businesses have the necessary catalysts to blow past electric-vehicle (EV) maker Tesla by 2026. 
Via The Motley Fool
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:ZLAB),(NASDAQ:NTBL),(NASDAQ:CRDF),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot. 
Via InvestorPlace
What Is the Dividend Payout for Johnson & Johnson Stock?
Here's a closer look at the healthcare behemoth's dividend. 
Via The Motley Fool
The 3 Most Undervalued S&P 500 Stocks to Buy in May 2024
These undervalued S&P 500 stocks are legacy names with strong fundamentals and a global presence. Buy them on the dip. 
Via InvestorPlace
Topics Stocks
Johnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Steady Dividend Plays: 3 Stocks Promising Reliable Payouts in 2024
Johnson & Johnson, PepsiCo, and Southern Company are three reliable dividend stocks providing consistent growth and attractive yields in 2024. 
Via InvestorPlace
Got $1,000? 3 Dividend Stocks to Buy and Hold Forever
Check out these healthcare stocks for some healthy payouts. 
Via The Motley Fool
Kenvue Layoffs 2024: What to Know About the Latest KVUE Job Cuts
Another round of job cuts at Kenvue has been announced. Here's what the latest Kenvue layoffs mean for KVUE stock. 
Via InvestorPlace
Topics Workforce
A Look At Pharma ETFs Post Q1 Earnings
Pharma ETFs have delivered mixed performances over the past month. 
Via Talk Markets
Topics ETFs
Johnson & Johnson's TARIS Platform - Goldman Sachs Outlines Potential For The Bladder Cancer Therapy
Johnson & Johnson unveils promising TARIS platform data for bladder cancer treatment, highlighting ease of administration and significant revenue potential. 
Via Benzinga
Shockwave Medical Reports First Quarter 2024 Financial Results
From Shockwave Medical, Inc.
Via GlobeNewswire
3 Biotech Stocks to Double Your Money in the Next 24 Months
The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates. 
Via InvestorPlace
Johnson & Johnson Advances Its Two Bladder Cancer Studies, Releases Latest Data
Johnson & Johnson's results in treating bladder and prostate cancer. Learn about TAR-210's efficacy in high-risk NMIBC patients and TAR-200's promising outcomes for BCG-unresponsive cases. 
Via Benzinga
Steady Dividend Plays: 3 Aristocrat Stocks to Own Now
Seeking steady income? These dividend aristocrat stocks offer dependable yields and a history of dividend growth. 
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: DecisionPoint Systems, Inc. (NYSE American - DPSI), AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Macatawa Bank Corporation (Nasdaq - MCBC), Shockwave Medical,
From Brodsky & Smith LLC
Via GlobeNewswire
Investor Alert: Are These 3 Spinoff Stocks Destined to Sizzle or Fizzle?
Investors often wonder what to make of spinoff stocks with these three recent moves to watch providing varying outcomes and future potential. 
Via InvestorPlace
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
After a painful two-year selloff, Pfizer shareholders may have finally gained a foothold after the company delivered a solid Q1 2024 earnings report 
Via MarketBeat
Johnson & Johnson: A Healthcare Giant That's Looking More Attractive By The Day
Johnson & Johnson is the largest healthcare products firm in the world by sales, spanning pharmaceuticals, medical devices, and consumer products. Plus, its shares only look more attractive as time... 
Via Talk Markets
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.